VIAV: $500M Offering Hits Stock After CEO Sold $22M

NEW YORK, June 2 —

Two weeks before Viavi Solutions filed prospectus supplements confirming a roughly $500 million equity raise, CEO Oleg Khaykin had already sold $22.1 million in company shares across four consecutive trading days. The offering, documented in a pair of 424B5 filings on May 19 and May 20, 2026, has since weighed on the stock. Khaykin's exit prices of $51 to $54 per share now sit well above where the market cleared the deal. Buyers who stepped in during the offering are underwater relative to where the CEO chose to reduce his own exposure.

The Selling Pattern

The timeline of Khaykin's sales is specific enough to be instructive. On May 5, he sold 104,552 shares at $54.61 and 20,238 shares at $54.77. On May 6, another 34,024 shares changed hands at $54.07. On May 7, 123,333 shares at $51.43. On May 8, the final tranche: 136,547 shares at $51.82. Total proceeds across four days: approximately $22.1 million, per Form 4 filings. Prices declined across the sequence — Khaykin was selling into a weakening stock before any public announcement of the offering arrived.

He was not the only seller. Per Form 4 filings, the 90-day window before the offering produced zero insider purchases and $26.51 million in total open-market sales across multiple officers and directors. Six individuals in aggregate, across roles ranging from the C-suite to the board, were net sellers in the weeks preceding the deal. Sophisticated investors treat coordinated distribution at this scale, timed ahead of a primary equity issuance, as a warning.

Then Came the Offering

On May 18, 2026, VIAVI filed an 8-K under Item 5.02, disclosing a change in directors or principal officers. The following day brought the first 424B5; the second landed May 20. A third 8-K appeared on May 21. Four SEC filings in four days, spanning a leadership disclosure and a major capital raise.

The offering totals approximately $500 million, with proceeds earmarked in part for debt repayment, per the prospectus supplements. Paying down debt with equity is a legitimate capital allocation choice, and a cleaner balance sheet lowers refinancing risk. The problem is sequencing: officers and directors were net sellers of equity at $51 to $54 per share in the days before the company turned around and asked the public market to buy equity at what appears to be a lower clearing price. Shareholders absorb the dilution; insiders had already adjusted their exposure at better prices.

The Business Is Not the Problem

Strip away the capital markets activity and Viavi Solutions presents a genuinely solid operation. Trailing twelve-month revenue came in at $1.37 billion with 42.8% revenue growth. Gross margin of 60.4% is well above what most hardware-adjacent businesses achieve, and free cash flow of $172 million confirms the profitability is real, not accounting-driven. The most recent quarterly earnings, reported April 29, 2026, showed EPS of $0.13 against a consensus estimate of $0.12. The two prior quarters followed the same script: $0.15 versus $0.13 estimated, and $0.22 versus $0.19 estimated.

Three consecutive beats, a 60% gross margin, and $172 million in free cash flow. The underlying machinery is performing. The quality question centers on the price paid to own a piece of it, and who was on the other side of that trade.

Where This Leaves Investors

A $500 million equity issuance against a company generating $172 million in annual free cash flow represents roughly three years of free cash flow absorbed in a single transaction. That is significant dilution, and it flows to existing shareholders before any debt payoff benefit returns to equity. The insiders who sold at $51 to $54 have effectively transferred that dilution risk onto the investors who stepped in as the stock declined.

The bull case requires believing the debt reduction is accretive, that free cash flow continues to compound, and that revenue growth sustains the multiple. The bears have a simpler argument: the people with the best information about Viavi's near-term trajectory spent two weeks converting their shares to cash at prices above where the deal cleared. The burden of proof shifts to management to demonstrate that the offering was a proactive balance sheet decision rather than a defensive one.

The next earnings report is the real checkpoint. Continued EPS beats would suggest the business is strong enough to grow into the dilution. A stumble, against a backdrop of insider exits and a large equity overhang, would be harder to dismiss. Investors watching the name should track the pace of debt reduction from the offering proceeds and whether free cash flow trajectory holds through the next two quarters.

Run the free Viavi Solutions Inc. deep-dive → basisreport.com/stock/viav

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why is VIAV stock falling?

Viavi Solutions fell after the company confirmed an approximately $500 million equity offering via prospectus supplements filed May 19–20, 2026, per SEC filings. The dilution overhang — combined with news that CEO Oleg Khaykin and other insiders had sold $26.51 million in shares in the preceding 90 days — pressured the stock as investors priced in the new share count and questioned management's timing.

Did Viavi Solutions CEO sell shares before the offering?

Yes. CEO Oleg Khaykin sold approximately 418,694 shares across May 5–8, 2026, at prices ranging from $51.43 to $54.77, generating roughly $22.1 million in proceeds, per Form 4 filings. The sales occurred two weeks before VIAVI confirmed the equity offering, which has since weighed on the stock.

What is the Viavi Solutions equity offering?

VIAVI filed two 424B5 prospectus supplements with the SEC on May 19 and May 20, 2026, confirming a public equity offering of approximately $500 million. Per news reporting, proceeds are directed in part toward debt repayment. The offering is dilutive relative to VIAVI's annual free cash flow of $172 million.

Is Viavi Solutions profitable?

By most measures, yes. VIAVI reported trailing twelve-month revenue of $1.37 billion with 42.8% revenue growth, a gross margin of 60.4%, and free cash flow of $172 million. The company has beaten earnings estimates in each of its last three quarters. The concern for investors is not business quality but rather whether the $500 million equity offering represents fair value relative to where insiders sold.

What are Viavi Solutions recent earnings results?

Viavi Solutions reported quarterly earnings on April 29, 2026, beating EPS estimates for the third consecutive quarter. The most recent result was $0.13 per share versus a $0.12 consensus estimate; the prior two quarters came in at $0.15 versus $0.13 estimated and $0.22 versus $0.19 estimated, per the company's 8-K filing and fundamentals data.